BACKGROUND/ PURPOSE: Extrahepatic portal vein obstruction (EHPVO) is an important cause of chronic portal hypertension in children. Although usually idiopathic in etiology, genetic and acquired thrombophilia have been implicated in EHPVO. Meso-Rex bypass is increasingly used to treat EHPVO in children. OBJECTIVE: The objective of this study is to assess the relationship of postoperative anticoagulation strategies and thrombophilic risk factors to the development of bypass thrombosis following the meso-Rex bypass. METHODS: Records of children who underwent meso-Rex bypass for EHPVO at a single institution from 1999 to 2009 were reviewed, and preoperative thrombophilia testing, perioperative anticoagulation strategies, and postoperative bypass patency based on imaging at last follow-up were examined. RESULTS: Sixty-five children with EHPVO underwent a first time meso-Rex bypass during the study period, and 9 of 65 (14 %) developed bypass thrombosis. The use of warfarin in the postoperative period was more common among children with thrombosed shunts than among those with open shunts [63 % vs. 20 %; OR, 6.5 (95 % CI, 1.3-31.5), p = 0.022]. The contribution of genetic or acquired thrombophilia to shunt thrombosis was inconclusive given variability in testing. CONCLUSIONS: Choice of anticoagulation following meso-Rex bypass may affect postoperative incidence of bypass thrombosis. Role of thrombophilic risk factors in the development of shunt thrombosis remains unclear.
BACKGROUND/ PURPOSE: Extrahepatic portal vein obstruction (EHPVO) is an important cause of chronic portal hypertension in children. Although usually idiopathic in etiology, genetic and acquired thrombophilia have been implicated in EHPVO. Meso-Rex bypass is increasingly used to treat EHPVO in children. OBJECTIVE: The objective of this study is to assess the relationship of postoperative anticoagulation strategies and thrombophilic risk factors to the development of bypass thrombosis following the meso-Rex bypass. METHODS: Records of children who underwent meso-Rex bypass for EHPVO at a single institution from 1999 to 2009 were reviewed, and preoperative thrombophilia testing, perioperative anticoagulation strategies, and postoperative bypass patency based on imaging at last follow-up were examined. RESULTS: Sixty-five children with EHPVO underwent a first time meso-Rex bypass during the study period, and 9 of 65 (14 %) developed bypass thrombosis. The use of warfarin in the postoperative period was more common among children with thrombosed shunts than among those with open shunts [63 % vs. 20 %; OR, 6.5 (95 % CI, 1.3-31.5), p = 0.022]. The contribution of genetic or acquired thrombophilia to shunt thrombosis was inconclusive given variability in testing. CONCLUSIONS: Choice of anticoagulation following meso-Rex bypass may affect postoperative incidence of bypass thrombosis. Role of thrombophilic risk factors in the development of shunt thrombosis remains unclear.
Authors: Benjamin Shneider; Sukru Emre; Roberto Groszmann; John Karani; Patrick McKiernan; Shiv Sarin; Harohalli Shashidhar; Robert Squires; Riccardo Superina; Jean de Ville de Goyet; Roberto de Franchis Journal: Pediatr Transplant Date: 2006-12
Authors: Graziela C M Schettino; Eleonora D T Fagundes; Mariza L V Roquete; Alexandre R Ferreira; Francisco J Penna Journal: J Pediatr (Rio J) Date: 2006 May-Jun Impact factor: 2.197
Authors: Sukru Emre; Christina Dugan; Tamara Frankenberg; Lisa Cooper Hudgins; Rosemarie Gagliardi; A Tarik Artis; Gonzalo Rodriguez-Laiz; Gabriel Gondolesi; Benjamin L Shneider; Nanda Kerkar Journal: HPB (Oxford) Date: 2009-05 Impact factor: 3.647
Authors: Christina Dalzell; Paola A Vargas; Kyle Soltys; Frank Di Paola; George Mazariegos; Nicolas Goldaracena Journal: Front Pediatr Date: 2022-04-25 Impact factor: 3.418